201 related articles for article (PubMed ID: 29541273)
1. Protection Efficacy of C5A Against Vaginal and Rectal HIV Challenges in Humanized Mice.
Gallay PA; Chatterji U; Kirchhoff A; Gandarilla A; Pyles RB; Baum MM; Moss JA
Open Virol J; 2018; 12():1-13. PubMed ID: 29541273
[TBL] [Abstract][Full Text] [Related]
2. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates.
Denton PW; Othieno F; Martinez-Torres F; Zou W; Krisko JF; Fleming E; Zein S; Powell DA; Wahl A; Kwak YT; Welch BD; Kay MS; Payne DA; Gallay P; Appella E; Estes JD; Lu M; Garcia JV
J Virol; 2011 Aug; 85(15):7582-93. PubMed ID: 21593172
[TBL] [Abstract][Full Text] [Related]
3. Immune reconstitution of the female reproductive tract of humanized BLT mice and their susceptibility to human immunodeficiency virus infection.
Olesen R; Wahl A; Denton PW; Garcia JV
J Reprod Immunol; 2011 Mar; 88(2):195-203. PubMed ID: 21256601
[TBL] [Abstract][Full Text] [Related]
4. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice.
Denton PW; Krisko JF; Powell DA; Mathias M; Kwak YT; Martinez-Torres F; Zou W; Payne DA; Estes JD; Garcia JV
PLoS One; 2010 Jan; 5(1):e8829. PubMed ID: 20098623
[TBL] [Abstract][Full Text] [Related]
5. HSV neutralization by the microbicidal candidate C5A.
de Witte L; Bobardt MD; Chatterji U; van Loenen FB; Verjans GM; Geijtenbeek TB; Gallay PA
PLoS One; 2011 May; 6(5):e18917. PubMed ID: 21573158
[TBL] [Abstract][Full Text] [Related]
6. Sublimable C5A delivery provides sustained and prolonged anti-HIV microbicidal activities.
Maskiewicz R; Bobardt M; Chatterji U; Gunaseelan S; Dezzutti CS; Penin F; Gallay PA
Antimicrob Agents Chemother; 2012 Jun; 56(6):3336-43. PubMed ID: 22430971
[TBL] [Abstract][Full Text] [Related]
7. C5A Protects Macaques from Vaginal Simian-Human Immunodeficiency Virus Challenge.
Veazey RS; Chatterji U; Bobardt M; Russell-Lodrigue KE; Li J; Wang X; Gallay PA
Antimicrob Agents Chemother; 2016 Jan; 60(1):693-8. PubMed ID: 26552985
[TBL] [Abstract][Full Text] [Related]
8. A Caulobacter crescentus Microbicide Protects from Vaginal Infection with HIV-1
Farr Zuend C; Nomellini JF; Smit J; Horwitz MS
J Virol; 2019 Sep; 93(18):. PubMed ID: 31243127
[TBL] [Abstract][Full Text] [Related]
9. Clinical development of microbicides for the prevention of HIV infection.
D'Cruz OJ; Uckun FM
Curr Pharm Des; 2004; 10(3):315-36. PubMed ID: 14754390
[TBL] [Abstract][Full Text] [Related]
10. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice.
Denton PW; Estes JD; Sun Z; Othieno FA; Wei BL; Wege AK; Powell DA; Payne D; Haase AT; Garcia JV
PLoS Med; 2008 Jan; 5(1):e16. PubMed ID: 18198941
[TBL] [Abstract][Full Text] [Related]
11. Long-Acting Rilpivirine (RPV) Preexposure Prophylaxis Does Not Inhibit Vaginal Transmission of RPV-Resistant HIV-1 or Select for High-Frequency Drug Resistance in Humanized Mice.
Melody K; Roy CN; Kline C; Cottrell ML; Evans D; Shutt K; Pennings PS; Keele BF; Bility M; Kashuba ADM; Ambrose Z
J Virol; 2020 Mar; 94(8):. PubMed ID: 31969438
[TBL] [Abstract][Full Text] [Related]
12. Prevention vaginally of HIV-1 transmission in humanized BLT mice and mode of antiviral action of polyanionic carbosilane dendrimer G2-S16.
Sepúlveda-Crespo D; Serramía MJ; Tager AM; Vrbanac V; Gómez R; De La Mata FJ; Jiménez JL; Muñoz-Fernández MÁ
Nanomedicine; 2015 Aug; 11(6):1299-308. PubMed ID: 25959924
[TBL] [Abstract][Full Text] [Related]
13. Oral pre-exposure prophylaxis by anti-retrovirals raltegravir and maraviroc protects against HIV-1 vaginal transmission in a humanized mouse model.
Neff CP; Ndolo T; Tandon A; Habu Y; Akkina R
PLoS One; 2010 Dec; 5(12):e15257. PubMed ID: 21203568
[TBL] [Abstract][Full Text] [Related]
14. Modeling HIV-1 Mucosal Transmission and Prevention in Humanized Mice.
Veselinovic M; Charlins P; Akkina R
Methods Mol Biol; 2016; 1354():203-20. PubMed ID: 26714714
[TBL] [Abstract][Full Text] [Related]
15. Acceptability of microbicidal vaginal rings and oral pre-exposure prophylaxis for HIV prevention among female sex workers in a high-prevalence US city.
Peitzmeier SM; Tomko C; Wingo E; Sawyer A; Sherman SG; Glass N; Beyrer C; Decker MR
AIDS Care; 2017 Nov; 29(11):1453-1457. PubMed ID: 28271718
[TBL] [Abstract][Full Text] [Related]
16. VRC01 antibody protects against vaginal and rectal transmission of human immunodeficiency virus 1 in hu-BLT mice.
Sun M; Li Y; Yuan Z; Lu W; Kang G; Fan W; Li Q
Arch Virol; 2016 Sep; 161(9):2449-55. PubMed ID: 27343044
[TBL] [Abstract][Full Text] [Related]
17. Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse Model.
Destache CJ; Mandal S; Yuan Z; Kang G; Date AA; Lu W; Shibata A; Pham R; Bruck P; Rezich M; Zhou Y; Vivekanandan R; Fletcher CV; Li Q
Antimicrob Agents Chemother; 2016 Jun; 60(6):3633-9. PubMed ID: 27044548
[TBL] [Abstract][Full Text] [Related]
18. A topical microbicide gel formulation of CCR5 antagonist maraviroc prevents HIV-1 vaginal transmission in humanized RAG-hu mice.
Neff CP; Kurisu T; Ndolo T; Fox K; Akkina R
PLoS One; 2011; 6(6):e20209. PubMed ID: 21673796
[TBL] [Abstract][Full Text] [Related]
19. HIV pre-exposure prophylaxis for women and infants prevents vaginal and oral HIV transmission in a preclinical model of HIV infection.
Kovarova M; Shanmugasundaram U; Baker CE; Spagnuolo RA; De C; Nixon CC; Wahl A; Garcia JV
J Antimicrob Chemother; 2016 Nov; 71(11):3185-3194. PubMed ID: 27494916
[TBL] [Abstract][Full Text] [Related]
20. Current Concepts for the IND-Directed Development of Microbicide Products to Prevent the Sexual Transmission of HIV.
Buckheit KW; Furlan-Freguia C; Ham AS; Buckheit RW
Curr Top Med Chem; 2016; 16(10):1118-34. PubMed ID: 26324047
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
